Agios Pharmaceuticals, Inc.
Ownership
Ownership Structure
Who owns Agios Pharmaceuticals, Inc. (AGIO)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 83.8% of the shares are freely tradable; institutional investors hold 108.6%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 9.64 | 5,754,957 | +9.9 | 03/31/2026 |
| Farallon Capital Management, L.L.C. | 9.52 | 5,684,000 | +10.2 | 03/31/2026 |
| Lynx1 Capital Management, LP | 5.71 | 3,408,937 | +30.5 | 06/30/2026 |
| State Street Corp | 5.64 | 3,364,879 | +8.3 | 03/31/2026 |
| D. E. Shaw & Co LP | 5.20 | 3,107,005 | +15.9 | 06/30/2026 |
| Armistice Capital, LLC | 4.55 | 2,716,000 | -10.5 | 03/31/2026 |
| Erste Asset Management GmbH | 4.53 | 2,704,900 | -3.6 | 03/31/2026 |
| Vanguard Capital Management, LLC | 4.41 | 2,632,316 | +0.0 | 03/31/2026 |
| Vanguard Portfolio Management, LLC | 4.37 | 2,611,035 | +0.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 3.53 | 2,110,203 | -1.1 | 08/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | 54,645 | 1,808,750 $ | Aug 4, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Aug 4, 2026 | Gheuens Sarah | Chief Medical Officer | Sell | 30,000 | 30.48 | 914,400 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.